A Phase 2 interventional study of DCC-2618 in Gastrointestinal Stromal Tumors, sponsored by Zai Lab (Shanghai) Co., Ltd.. Completed at 9 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-03.
Sponsored by Zai Lab (Shanghai) Co., Ltd. (part of Zai Lab Limited) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in Gastrointestinal Stromal Tumors with a site in China — 24 open to participants now, 28 under way, 4 of them phase 3. Gastrointestinal Stromal Tumors · China.
Among the 69 studies in Gastrointestinal Stromal Tumors with a site in China, this one is the 39th largest by enrollment of the 46 interventional ones that give a count, is one of 7 that started in 2020, is one of 11 in phase 2, and was the 26th registered.
343 studies on the registry are indexed under Gastrointestinal Stromal Tumors; 61 are open to participants now.
Browse Gastrointestinal Stromal Tumors studies →24 of the 69 studies in Gastrointestinal Stromal Tumors with a site in China are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in China, United States, Argentina and 17 more countries
Ages 18+
Ningbo Newbay Technology Development Co., Ltd · Sites in China, Korea, Republic of
Ages 18+
Affiliated Hospital to Academy of Military Medical Sciences · Sites in China
Ages 18–85
GlaxoSmithKline · Sites in China, United States, Australia and 16 more countries
Ages 18+
Huazhong University of Science and Technology · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 49 Gastrointestinal Stromal Tumors studies recruiting now, 38 (78%) set no upper age limit and 4 (8%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 13 · Phase 3 9 · Phase 4 2
First in 2002; this study’s year is marked. 7 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 39 is below the median of 50 across 252 interventional studies indexed under Gastrointestinal Stromal Tumors.
Median enrollment 100 across the 46 interventional studies, 181 across the 22 observational. Of the 21 that completed or were terminated, 8 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 69 have an industry lead sponsor. The 10 most frequent:
This study is registered under Zai Lab (Shanghai) Co., Ltd., one of the names counted as Zai Lab Limited. Under that name alone:
Zai Lab (Shanghai) Co., Ltd. is the lead sponsor of 25 studies on the registry; 8 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
Zai Lab Limited has 2 studies filed under Gastrointestinal Stromal Tumors — fewer than ten, so there is no comparison to draw.
7 of the studies in Gastrointestinal Stromal Tumors with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05245968Taiho Pharmaceutical Co., Ltd.A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101) | 2026-12 |
| NCT05489237IDRX, Inc., a wholly owned subsidiary of GSK, LLCFirst-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors | 2027-03-10 |
| NCT06926374Chinese University of Hong KongProspective Evaluation of Cornerstone Robotics Sentire Surgical System in Major Gastrointestinal and Urologic Surgery | 2027-04 |
| NCT07581977Affiliated Hospital to Academy of Military Medical SciencesA Novel Two-Tooth Clip for ESD and EFTR of GIST | 2027-04-24 |
| NCT07559864Jian LiComparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment | 2027-06-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 69 studies in Gastrointestinal Stromal Tumors with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this trial is to evaluate the progress free survival (PFS) of DCC-2618 in patients with advanced gastrointestinal stromal tumors who have progressed with prior anticancer therapies based on independent radiologic review.
The primary objective of this trial is to evaluate the progress free survival (PFS) of DCC-2618 in patients with advanced gastrointestinal stromal tumors who have progressed with prior anticancer therapies based on independent radiologic review. This study enrolled 39 subjects of 9 sites in China mainland, and all enrolled subjects received DCC-2618 after enrollment as treatment.
The study used EDC to collect patient data and IRT system for patient randomization, using Imaging Endpoints as the central image to evaluate the PFS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DCC-2618 drug is 50mg per tablet, 150mg once a day, with 28 days as a treatment cycle.
Drug: DCC-2618
Oral kinase inhibitor
Also known as: Ripretinib
Progression-Free Survival (PFS)
Progression-Free Survival (PFS) is defined as the time from the first dose of study drug to the first occurrence of disease progression based on independent radiology review or death due to any cause (whichever occurred first).
Time frame: Approximately 10 months since the first subject enrolled.
Objective Response Rate (ORR)
The objective response rate (ORR) is defined as the percentage of participants who achieved confirmed complete response (CR) or partial responses (PR) based on independent radiology review.
Time frame: Approximately 15 months since the first subject enrolled.
Overall Survival (OS)
Overall survival (OS) is defined as the time from the first dose of study drug to all-cause death.
Time frame: Approximately 28 months since the first subject enrolled.
Time to Best Response (TBR)
Time to Best Response(TBR) based on independent radiology review is defined as the duration from the date of the first dose of the investigational drug to the date of confirming the best response.
Time frame: Approximately 15 months since the first subject enrolled.
Disease Control Rate (DCR) (Confirmed CR + Confirmed PR + SD) for 12 Weeks
Disease control rate (DCR) based on independent radiology review (confirmed CR + confirmed PR + SD for 12 weeks)
Time frame: Approximately 15 months since the first subject enrolled.
Between April 2020 and August 2020, 39 patients were enrolled, and all received at least one dose of study drug.
| Milestone | DCC-2618 |
|---|---|
| Started | 39 |
| Completed | 20 |
| Not completed | 19 |
| Withdrew: Remained on treatment | 6 |
| Withdrew: Survival follow-up | 11 |
| Withdrew: Withdrawal of informed consent | 1 |
| Withdrew: Lost to follow-up | 1 |
Progression-Free Survival (PFS) is defined as the time from the first dose of study drug to the first occurrence of disease progression based on independent radiology review or death due to any cause (whichever occurred first).
| months | DCC-2618 |
|---|---|
| Progression-Free Survival (PFS) | 6.44 (2.89 to 8.31) |
The objective response rate (ORR) is defined as the percentage of participants who achieved confirmed complete response (CR) or partial responses (PR) based on independent radiology review.
| Participants | DCC-2618 |
|---|---|
| Objective Response Rate (ORR) | 8 |
Overall survival (OS) is defined as the time from the first dose of study drug to all-cause death.
| months | DCC-2618 |
|---|---|
| Overall Survival (OS) | 25.56 (11.73 to NA) |
Time to Best Response(TBR) based on independent radiology review is defined as the duration from the date of the first dose of the investigational drug to the date of confirming the best response.
| months | DCC-2618 |
|---|---|
| Time to Best Response (TBR) | 2.25 (1.0 to 11.9) |
Disease control rate (DCR) based on independent radiology review (confirmed CR + confirmed PR + SD for 12 weeks)
| Participants | DCC-2618 |
|---|---|
| Disease Control Rate (DCR) (Confirmed CR + Confirmed PR + SD) for 12 Weeks | 20 |
Collected over From the date of the first dose of study treatment up to 30 days following study treatment discontinuation. Up to approximately 28 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DCC-2618 | 20/39 (51.3%) | 10/39 (25.6%) | 39/39 (100%) |
| Event | DCC-2618 |
|---|---|
| Gastrointestinal haemorrhageGastrointestinal disorders | 3/39 |
| AnaemiaBlood and lymphatic system disorders | 2/39 |
| PyrexiaGeneral disorders | 1/39 |
| Cardiac dysfunctionCardiac disorders | 1/39 |
| Acute kidney injuryRenal and urinary disorders | 1/39 |
| Abdominal pain upperGastrointestinal disorders | 1/39 |
| Acute myocardiac infarctionCardiac disorders | 1/39 |
| PneumoniaInfections and infestations | 1/39 |
| Inra-abdomina fluid collectionGastrointestinal disorders | 1/39 |
| Aabdominal painGastrointestinal disorders | 1/39 |
| Event | DCC-2618 |
|---|---|
| AnaemiaBlood and lymphatic system disorders | 26/39 |
| AlopeciaSkin and subcutaneous tissue disorders | 17/39 |
| AstheniaGeneral disorders | 13/39 |
| Bilirubin conjugated increasedInvestigations | 13/39 |
| Blood bilirubin increasedInvestigations | 13/39 |
| Weight decreasedInvestigations | 10/39 |
| Abdominal distensionGastrointestinal disorders | 9/39 |
| HypokalaemiaMetabolism and nutrition disorders | 9/39 |
| MyalgiaMusculoskeletal and connective tissue disorders | 9/39 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 9/39 |
| Age, Categorical(Participants) | DCC-2618 |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 32 |
| >=65 years | 7 |
| Age, Continuous(years) | DCC-2618 |
|---|---|
| Median | 55.1 (36.8 to 73.6) |
| Sex: Female, Male(Participants) | DCC-2618 |
|---|---|
| Female | 12 |
| Male | 27 |
| Race (NIH/OMB)(Participants) | DCC-2618 |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 39 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | DCC-2618 |
|---|---|
| China | 39 |
| ECOG performance status(Participants) | DCC-2618 |
|---|---|
| 0 | 7 |
| 1 | 28 |
| 2 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2020 to primary completion in Feb 2021, 10 months.
Results were first posted in Mar 2025, 4 years after primary completion.
Of 47 phase 2 interventional studies under Gastrointestinal Stromal Tumors, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 92. This study's 10 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ripretinib
Gastrointestinal Stromal Tumors →
Zai Lab (Shanghai) Co., Ltd. →